Stiftingtalstraße 14 | 8010 Graz, Austria

📢 We’re proud to unveil exciting news from Cycuria Therapeutics.

We’ve secured grant funding from two leading Austrian national bodies, FFG and AWS, and today announce our newly appointed Advisory Board, which unites distinguished leaders in corporate strategy, clinical haemato-oncology, protein engineering, early-stage drug discovery and development.

Our distinguished advisory board consists of John Haurum, Bertolt Kreft, Andrew Wei, Felix Wieland and Walter Nickel.

Read the full Press Release here: Cycuria Press Release

Share:

More Posts

At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.